Filing summary
Entity and period: The supplied filing is Ruthigen, Inc.’s unaudited Form 10-Q for the quarter ended December 31, 2014 (fiscal 2015 third quarter), not a Pulmatrix filing. The period mismatch should be resolved before relying on this summary.
Business context and development
Ruthigen was a pre-revenue biopharmaceutical company developing RUT58-60, a hypochlorous-acid-based candidate intended to prevent and treat infections in surgery, initially abdominal surgery. The company reported that its IND had become effective in June 2014, it completed a 21-day skin-irritation trial, and it began a Phase 1/2 abdominal-surgery study in October, with enrollment beginning in November. At the filing date, it was enrolling the first 20 patients in the Phase 1 safety portion and reported no serious adverse events to date. The company planned to assess safety data before proceeding with Phase 2 and Phase 3 development.
Financial highlights
| Metric | Three months ended Dec. 31, 2014 | Nine months ended Dec. 31, 2014 | Comparable 2013 period |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Operating expenses | $1.716 million | $5.150 million | $0.658 million and $2.129 million |
| Net loss | $1.712 million | $5.137 million | $0.658 million and $2.129 million |
| Basic and diluted loss per share | $0.35 | $1.07 | $0.33 and $1.06 |
| Net cash used in operating activities | Not presented for the quarter | $4.227 million | $1.577 million |
For the nine months, research and development expense rose 81% to $1.924 million; selling, general and administrative expense rose 203% to $3.226 million. Management attributed increases to RUT58-60 development and clinical-trial preparation, public-company costs, and stock-based compensation. No meaningful operating margin is available because the company had no revenue.
At December 31, 2014, cash was $11.570 million, working capital was $11.194 million, total assets were $11.874 million, and total current liabilities were $575,000. The filing reports no interest-bearing debt. Cash declined $4.001 million from March 31, 2014. Nine-month investing cash use was $103,000; financing provided $329,000, including IPO-related proceeds partly offset by repayment of former-parent advances.
Changes, outlook, and risks
- Net loss increased from $2.129 million to $5.137 million for the nine-month comparison, alongside higher R&D and G&A spending.
- Management estimated existing cash would fund operations through the quarter ending March 31, 2016, but said further funding would be needed to execute development and pursue regulatory approval. No new financing commitment was reported.
- Management estimated approximately $50 million in total operating expense to bring RUT58-60 through its FDA-approval goal. It expected R&D and G&A costs to continue increasing; profitability was not assured.
- The license and supply agreement with former parent Oculus included up to $8 million in milestone payments, none accrued at December 31, 2014. Employment agreements created potential cash severance of $1.144 million; CEO and CFO arrangements also provide specified benefits and equity acceleration in certain circumstances.
- Key risks include clinical and regulatory failure or delay, inability to raise capital on acceptable terms, and the possibility that the company may need to curtail research or other activities. The filing reported no material legal proceedings, no material changes to previously disclosed risk factors, and no material off-balance-sheet arrangements.
- The filing lists a January 8, 2015 securities purchase agreement as an exhibit but does not provide clear transaction terms in the supplied text.
Important facts for investors to verify
- Confirm that Ruthigen, rather than Pulmatrix, is the intended company and that December 31, 2014 is the intended reporting period.
- Check subsequent filings for financing transactions, cash runway changes, and any resulting dilution.
- Verify the Phase 1/2 trial enrollment, safety findings, and subsequent regulatory and clinical milestones.
- Review the Oculus license terms and potential milestone obligations, plus employment-related severance and change-of-control provisions.
- Assess actual cash burn against management’s March 31, 2016 runway estimate and the stated approximate $50 million development-cost estimate.